T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
WSFS Financial
WSFS
$4.17B
| $23.3M | ﹤0.01% |
923,721
+463,131
| +101% | +$11.8M |
|
|
NFX
1077
DELISTED
Newfield Exploration
NFX
| $23.3M | ﹤0.01% |
662,710
+413,800
| +166% | +$12.5M |
|
1078
Principal Financial Group
PFG
$24.6B
| $23.2M | ﹤0.01% |
451,960
+4,900
| +1% | +$246K |
|
1079
KLA
KLAC
$274B
| $23.2M | ﹤0.01% |
3,978,050
+376,000
| +10% | +$2.41M |
|
1080
Protolabs
PRLB
$2.21B
| $23.1M | ﹤0.01% |
329,330
+156,415
| +90% | +$10.6M |
|
1081
Robert Half
RHI
$4.48B
| $22.8M | ﹤0.01% |
377,053
-17,900
| -5% | -$1.08M |
|
|
BHBK
1082
DELISTED
Blue Hills Bancorp, Inc.
BHBK
| $22.7M | ﹤0.01% |
1,720,064
+461,532
| +37% | +$6.04M |
|
1083
FIVE9
FIVN
$2.53B
| $22.7M | ﹤0.01% |
4,082,630
+2,068,790
| +103% | +$8.96M |
|
1084
Commault Systems
CVLT
$6.26B
| $22.6M | ﹤0.01% |
518,230
-717,318
| -58% | -$33M |
|
|
NEWP
1085
DELISTED
NEWPORT CORP
NEWP
| $22.6M | ﹤0.01% |
1,184,490
-19,400
| -2% | -$375K |
|
1086
Sally Beauty Holdings
SBH
$1.55B
| $22.5M | ﹤0.01% |
654,700
-39,883
| -6% | -$1.29M |
|
1087
Church & Dwight Co
CHD
$24B
| $22.4M | ﹤0.01% |
524,726
-10,370
| -2% | -$432K |
|
|
HZNP
1088
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $22.4M | ﹤0.01% |
862,000
-4,700
| -0.5% | -$86.2K |
|
|
DF
1089
DELISTED
Dean Foods Company
DF
| $22.3M | ﹤0.01% |
1,349,608
-564,130
| -29% | -$9.68M |
|
1090
KeyCorp
KEY
$24.6B
| $22.3M | ﹤0.01% |
1,575,407
-4,500
| -0.3% | -$61.8K |
|
1091
Marriott Vacations Worldwide
VAC
$4.17B
| $22.2M | ﹤0.01% |
273,968
+21,800
| +9% | +$1.69M |
|
1092
Koppers
KOP
$874M
| $22.2M | ﹤0.01% |
1,127,828
+1,180
| +0.1% | +$23.7K |
|
1093
Open Text
OTEX
$6.02B
| $22.1M | ﹤0.01% |
837,076
-1,254
| -0.1% | -$35.8K |
|
1094
Labcorp
LH
$26.2B
| $22M | ﹤0.01% |
202,655
+38,682
| +24% | +$3.98M |
|
1095
Crocs
CROX
$6.36B
| $21.9M | ﹤0.01% |
1,856,150
+71,630
| +4% | +$803K |
|
|
HMIN
1096
DELISTED
HOMEINNS HOTEL GROUP SPONSORED ADR
HMIN
| $21.8M | ﹤0.01% |
922,919
+79,971
| +9% | +$2.07M |
|
|
LDL
1097
DELISTED
Lydall, Inc.
LDL
| $21.8M | ﹤0.01% |
687,090
-571,720
| -45% | -$17.5M |
|
|
DNB
1098
DELISTED
Dun & Bradstreet
DNB
| $21.8M | ﹤0.01% |
169,535
+45,600
| +37% | +$5.71M |
|
|
BCR
1099
DELISTED
CR Bard Inc.
BCR
| $21.6M | ﹤0.01% |
128,894
+8,190
| +7% | +$1.4M |
|
|
VAL
1100
DELISTED
Valspar
VAL
| $21.5M | ﹤0.01% |
255,975
+37,900
| +17% | +$3.26M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.